Reina Kakefuda
Overview
Explore the profile of Reina Kakefuda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
193
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uesato N, Kitagawa Y, Matsuo Y, Miyagawa N, Inagaki K, Kakefuda R, et al.
Biol Pharm Bull
. 2023 Sep;
46(9):1223-1230.
PMID: 37661402
Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation and the destruction of bone and cartilage in affected joints. One of the unmet medical needs in the treatment of...
2.
Uesato N, Inagaki K, Miyagawa N, Kitagawa Y, Kakefuda R, Matsuo Y, et al.
Biol Pharm Bull
. 2020 Dec;
43(12):1884-1892.
PMID: 33268706
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation and structural destruction of the joints. Bone damage occurs in an early stage after onset and osteoclast activation...
3.
Uesato N, Miyagawa N, Inagaki K, Kakefuda R, Kitagawa Y, Matsuo Y, et al.
Biol Pharm Bull
. 2020 Feb;
43(2):325-333.
PMID: 32009119
Colony stimulating factor 1 (CSF1) receptor (CSF1R) is a receptor protein-tyrosine kinase specifically expressed in monocyte-lineage cells, such as monocytes and macrophages. In this study, we characterized the pharmacological properties...
4.
Maekawa M, Tadaki H, Tomimoto D, Okuma C, Sano R, Ishii Y, et al.
Biol Pharm Bull
. 2019 Nov;
42(11):1906-1912.
PMID: 31685773
Tumor necrosis factor-α (TNF-α) converting enzyme/a disintegrin and metalloproteinase domain-containing protein 17 (TACE/ADAM17) is a key sheddase that releases TNF-α from its inactive precursor and is thought as a new...
5.
Abe H, Kikuchi S, Hayakawa K, Iida T, Nagahashi N, Maeda K, et al.
ACS Med Chem Lett
. 2014 Jun;
2(4):320-4.
PMID: 24900312
Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) represents a promising strategy for the discovery of a new generation of anticancer chemotherapeutics. Our synthetic efforts, beginning from the lead...
6.
Yamaguchi T, Kakefuda R, Tanimoto A, Watanabe Y, Tajima N
Inflamm Res
. 2012 Jan;
61(5):445-54.
PMID: 22245957
Objective And Design: To examine the effects of a mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2-inhibitor, JTP-74057, on inflammatory arthritis development, and compare its anti-arthritic effect with leflunomide. Materials: Human,...
7.
Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T
Int J Oncol
. 2011 Apr;
39(1):23-31.
PMID: 21523318
The MAPK pathway is one of the most important pathways for novel anticancer drug development. We performed high-throughput screening for compounds that induce expression of p15INK4b, and identified JTP-74057 (GSK1120212),...
8.
Sawada H, Nagahiro K, Kikukawa Y, Ban S, Kakefuda R, Shiomi T, et al.
Biol Pharm Bull
. 2003 Jul;
26(7):1025-7.
PMID: 12843632
Duchenne muscular dystrophy is known to be caused by a defective gene of dystrophin, a 427-kDa cytoskeletal protein, but the effective therapeutic drug is presently unavailable. We previously reported that...